SCHEMBL20031353

SCHEMBL20031353

CN(C)Cc1cc(-c2ccccc2)on1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.62
RAB9A P51151 5/20 0.60
L3MBTL1 Q9Y468 3/20 0.60
TDP1 Q9NUW8 2/20 0.60
ALDH1A1 P00352 2/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
NPC1 O15118 3/20 0.50
CXCR1 P25024 2/20 0.50
USP30 Q70CQ3 1/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
CASP3 P42574 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46
SLC6A9 P48067 1/20 0.46
SCD5 Q86SK9 1/20 0.44
TAAR1 Q96RJ0 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12092546 0.85 NOTUM (0.44) NOTUMRAB9AL3MBTL1TDP1ALDH1A1
SCHEMBL10274629 0.80 NOTUM (0.68) NOTUMRAB9AL3MBTL1TDP1ALDH1A1
SCHEMBL28319063 0.77 NOTUM (0.64) NOTUMRAB9AL3MBTL1TDP1ALDH1A1
SCHEMBL14552880 0.77 RAB9A (0.67) NOTUMRAB9AL3MBTL1TDP1ALDH1A1
SCHEMBL1544128 0.77 NOTUM (1.00) NOTUMRAB9AL3MBTL1TDP1ALDH1A1
SCHEMBL1437486 0.77 NOTUM (0.68) NOTUMRAB9AL3MBTL1TDP1ALDH1A1
SCHEMBL3396472 0.77 NOTUM (0.68) NOTUMRAB9AL3MBTL1TDP1ALDH1A1
SCHEMBL28225146 0.77 NOTUM (0.68) NOTUMRAB9AL3MBTL1TDP1ALDH1A1
SCHEMBL2538472 0.77 NOTUM (0.68) NOTUMRAB9AL3MBTL1TDP1ALDH1A1
SCHEMBL1457325 0.77 NOTUM (0.68) NOTUMRAB9AL3MBTL1TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11014912-B2 Cyanopyrrolidine derivatives with activity as inhibitors of USP30 MISSION THERAPEUTICS LIMITED (GB) 2021-05-25 US disclosed
EP-3519385-B1 CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 MISSION THERAPEUTICS LTD (GB) 2020-11-18 EP disclosed
WO-2018060689-A1 CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 MISSION THERAPEUTICS LIMITED (GB) 2018-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11014912-B2 Cyanopyrrolidine derivatives with activity as inhibitors of USP30 USP30, USP39, USP28 NOTUM 2480/4885RAB9A 3387/4885L3MBTL1 1495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.